<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5233">
  <stage>Registered</stage>
  <submitdate>5/11/2015</submitdate>
  <approvaldate>5/11/2015</approvaldate>
  <nctid>NCT02599792</nctid>
  <trial_identification>
    <studytitle>Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656</studytitle>
    <scientifictitle>A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. KalydecoÂ® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP656.1002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CTP-656
Treatment: drugs - Placebo for CTP-656
Treatment: drugs - Kalydeco

Experimental: CTP-656, 150 mg - Single Oral Dose

Active Comparator: Kalydeco, 150 mg - Single oral dose

Experimental: CTP-656, 75 mg or matching placebo - Subjects will be administered 75 mg CTP-656 for 7 days.

Experimental: CTP-656, 150 mg or matching placebo - Subjects will be administered 150 mg CTP-656 for 7 days.

Experimental: CTP-656, high dose or matching placebo - Subjects will be administered up to 300 mg CTP-656 for 7 days.


Treatment: drugs: CTP-656


Treatment: drugs: Placebo for CTP-656


Treatment: drugs: Kalydeco


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability - adverse events categorized by body system and MedDRA term</outcome>
      <timepoint>7 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Measure exposure of test articles using area under the concentration time curve (AUC)</outcome>
      <timepoint>96 hours</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adults between 18 and 50 years of age, inclusive

          -  Body weight = 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at
             screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of
             Gilbert's syndrome or gastrointestinal (GI) conditions

          -  PR interval = 220 msec or QRS duration = 120 msec or QTcF interval &gt; 450 msec obtained
             at screening visit or prior to the first dose of study drug

          -  Liver function tests greater than the upper limit of normal.

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody at screening

          -  Urinalysis positive for greater than trace blood, protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use.

          -  Inability to comply with food and beverage restrictions during study participation.

          -  Donation or blood collection or acute loss of blood prior to screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital> - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Concert Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and
      multiple-ascending doses of CTP-656 dosed for 7 days.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02599792</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lana Pilja</name>
      <address>Concert Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>